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Purpose: Data comparing real-world effectiveness
of the glucagon-like peptide-1 receptor agonists (GLP-
1RAs) exenatide once weekly (QW) and liraglutide in
the treatment of type 2 diabetes (T2D) are limited.
Furthermore, there is limited information on exenatide
QW or liraglutide response by glycemic control and
insulin use status. This study identiﬁes 1-year glyco-
sylated hemoglobin (HbA1c) and weight outcomes
with exenatide QW and liraglutide in the real-world
setting overall and in insulin-naive patients with
uncontrolled T2D.
Methods: This retrospective cohort study using
national electronic medical record data compared
1-year HbA1c and weight outcomes in patients with
T2D prescribed exenatide QW or liraglutide. Included
patients were adults (Z18 years old) with T2D who
were GLP-1RA naive when newly prescribed exena-
tide QW or liraglutide between January 1, 2012, and
March 31, 2013 (index date). Outcomes were re-
ported descriptively overall and in subsets of insulin-
naive patients with baseline HbA1c Z7.0% or
Z9.0%. Multivariable linear regression analyses were
performed to estimate adjusted change in HbA1c and
weight.
Findings: The study included 808 exenatide QW
and 4333 liraglutide patients. Mean (SD) age was 57
(11) years in both groups. Mean baseline HbA1c was
8.3% (1.5%) in exenatide QW patients and 8.4%
(1.6%) in liraglutide patients (P ¼ 0.66); 16 (2%) of
the exenatide QW and 1099 (25.4%) of the liraglutide
patients were newly prescribed insulin on the index
date (P o 0.001). Adjusted mean HbA1c change at
1 year was 0.37% (95% CI, 0.53% to 0.21%)] 2016for exenatide QW and 0.37% (95% CI, 0.55% to
0.18%) for liraglutide. Adjusted HbA1c reduction
was more pronounced in insulin-naive patients with
baseline HbA1c Z7.0% (0.71% and 0.80% for
the exenatide QW and liraglutide patients, respec-
tively, P 4 0.05) and Z9.0% (1.73% and 1.57%
for exenatide QW and liraglutide patients, respec-
tively, P 4 0.05). Mean (adjusted) weight loss was
2.22 kg (95% CI, 3.06 to 1.37 kg) with exena-
tide QW and 2.21 kg (95% CI, 3.18 to 1.23 kg)
with liraglutide.
Implications: Exenatide QW and liraglutide lead to
similar HbA1c and weight reductions at 1 year in the
real-world setting. Greater HbA1c reductions occurred
in insulin-naive patients with baseline HbA1c Z7.0%.
Both agents are appropriate options for patients
needing antidiabetes therapy to lower HbA1c while
promoting weight loss. (Clin Ther. 2016;]:]]]–]]])
& 2016 The Authors. Published by Elsevier HS
Journals, Inc.
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Effective management of type 2 diabetes (T2D) can be
a signiﬁcant challenge for patients, practitioners, and1
Clinical Therapeuticshealth care systems. T2D is a progressive disease
associated with high comorbidity.1 Thus, even
adherent patients eventually require multiple diabetes
medications to manage hyperglycemia and reduce the
risk of developing diabetes complications. Although
consistent in recommending metformin as ﬁrst-line
therapy, guidelines are less speciﬁc with second-line
treatment, recommending that practitioners select
second-line therapy based on patient-speciﬁc treat-
ment goals and product characteristics.2,3
Glucagon-like peptide-1 receptor agonists (GLP-
1RAs) are beneﬁcial as second-line T2D therapeutic
alternatives because they are associated with signiﬁ-
cant reductions in glycosylated hemoglobin (HbA1c)
and weight with low risk of hypoglycemia.2
Numerous GLP-1RAs are approved for treatment of
T2D. Exenatide dosed BID was the ﬁrst GLP-1RA,
approved in 2005. Exenatide BID targets mealtime, or
postprandial, glucose and is approved as add-on
treatment to basal insulin based on complementary
pharmacologic effects on prandial and fasting glycemia.4
Liraglutide dosed once daily was the second GLP-1RA
approved (2010), followed by a once-weekly (QW)
formulation of exenatide (2012). Albiglutide and dula-
glutide were approved in late 2014; both are dosed once
weekly.
Exenatide QW5 and liraglutide6 are GLP-1RAs
commonly used in the United States. They are indi-
cated as add-on therapy adjunct to diet and exercise to
improve glycemic control in adults with T2D. Clinical
trials have found both agents to be effective and
generally well tolerated.7,8 Although they differ in
injection frequency, differentiation in terms of efﬁcacy
and tolerability is complex but limited because of
mixed evidence.7,9 A head-to-head comparison of
liraglutide versus exenatide QW found a small but
statistically greater HbA1c reduction of 0.21% (95%
CI, 0.08–0.33) for liraglutide versus exenatide QW.9
Common adverse events were reported more often in
the liraglutide group, including nausea, diarrhea, and
vomiting. Furthermore, more patients taking liraglu-
tide than exenatide QW discontinued the study
because of adverse events.9 A recent medication
adherence study found that patients receiving
exenatide QW were more likely to be adherent than
patients receiving liraglutide.10
Given the differences in tolerability and adherence,
we hypothesized the differences in HbA1c outcomes
between exenatide QW and liraglutide seen in the2head-to-head clinical trial may not be observed in a
real-world setting. A prior study evaluated glycemic
control and weight outcomes of exenatide QW versus
liraglutide,11 but the study outcome period was
limited to 6 months. Furthermore, there is limited
information on response to exenatide QW or
liraglutide according to glycemic control and insulin
use status, which would be of use to prescribers
considering the addition of GLP-1RA to therapy.
Therefore, the purpose of this study was to compare
real-world HbA1c and weight outcomes at 1 year in
patients with T2D prescribed exenatide QW or lir-
aglutide overall and in subsets of insulin-naive patients
with uncontrolled T2D.PATIENTS AND METHODS
Study Design and Timeline
A retrospective cohort study was conducted using a
national electronic medical record database to assess
1-year HbA1c and weight outcomes in adult patients
with T2D newly prescribed exenatide QW or liraglu-
tide between January 1, 2012, and March 31, 2013.
Data Source
This study used the Quintiles electronic medical
record (Q-EMR) database, a national ambulatory care
dataset. At the time of this study, Q-EMR included
patient-level data on438 million individuals from 49
states and the District of Columbia. Q-EMR includes
demographic data, vital signs, International Classiﬁ-
cation of Diseases, Ninth Revision (ICD-9) –based
medical diagnoses, laboratory tests and results, pro-
cedures, insurance information, prescription medica-
tion orders, and medication history. Data were
available through March 31, 2014.
Cohort Selection
The study cohort was drawn from adult patients
with a diagnosis of T2D (ICD-9 codes 250.*0 or
250.*2, taking a diabetes drug, HbA1c Z6.5%, or
2 consecutive fasting blood glucose valuesZ126 mg/dL).
Included patients were GLP-1RA naive when newly
prescribed exenatide QW or liraglutide between
January 1, 2012, and March 31, 2013 (index date),
which allowed for identiﬁcation of baseline character-
istics before the index date and 1-year outcomes data
using the available data. Included patients had HbA1c
values on the index date (60 to þ30 days) andVolume ] Number ]
C. McAdam-Marx et al.at 1 year (60 days) after the index date and had
clinical activity in the database for at least 13 months
before and 1 year after the index date. Patients with
type 1 diabetes, women with gestational diabetes, those
with prescription orders for 2 different GLP-1RAs on
the index date, and those prescribed a different GLP-
1RA within 30 days after index date were excluded.
Outcome Variables
Primary study outcomes were changes in HbA1c
and weight from index date to 1-year follow-up.
Secondary outcomes included proportion of patients
with HbA1c o7.0% at 1-year follow-up in those with
baseline HbA1c Z7.0%. In addition, subgroup anal-
yses were conducted to investigate outcomes in pa-
tients with poor glycemic control at baseline (HbA1c
Z7.0% and Z9.0%) who were not treated with
insulin on or up to 13 months before the index date
(insulin naive).
Independent Variables
Additional baseline characteristics were captured in
the 13 months before the index date to describe the
study cohort and to control for confounding, includ-
ing age, sex, race, baseline HbA1c, body mass index,
weight, blood pressure, select comorbidities (by diag-
nosis codes), and the Charlson Comorbidity Index
(CCI).12 The specialty of the patient’s practitioner
was also captured and reported as primary care,
endocrinology, or other.
Diabetes medication use at baseline (up to 13 months
before the index date) was reported at the class level and
by the number of medication classes. Diabetes medica-
tions were categorized as metformin, sulfonylureas,
thiazolidinediones, dipeptidyl peptidase-4 inhibitors,
pramlintide, and other (α-glucosidase inhibitors, dopa-
mine agonists, meglitinide analogues). Sodium glucose
co-transporter 2 inhibitors were not available at the time
of the study. Baseline insulin use was further categorized
as pre-index use or insulin initiated on index date.
Statistical Analysis
Descriptive statistics were used to describe baseline
characteristics by treatment groups. Independent
t tests and χ2 tests were used to detect differences in
continuous and categorical variables, respectively.
Independent t tests were used to determine if the
change in HbA1c or weight differed by treatment. A χ2
test was used to report the statistical signiﬁcance] 2016between the proportions of patients not at goal at
baseline who attained HbA1c goal (HbA1c o7.0%) at
follow-up by treatment group.
Multivariate linear regression was used to assess
adjusted changes in HbA1c and weight with exenatide
QW relative to liraglutide. Multivariate logistic regres-
sion was used to report the odds of attaining HbA1c
o7.0% at follow-up for exenatide QW versus liraglu-
tide in patients with baseline HbA1c Z7.0. Initial
regression models controlled for confounders, including
baseline HbA1c and weight, demographic character-
istics, and clinical and treatment characteristics. Parsi-
monious models were identiﬁed using stepwise
backward selection. Final models controlled for age,
sex, baseline HbA1c and weight, practitioner specialty,
coronary heart disease, microvascular complications,
CCI, and baseline use of insulin and oral diabetes
medications. The ﬁnal multivariate linear regression
models were used to estimate the adjusted mean change
in HbA1c and weight by treatment group.
All statistical tests were performed using SAS soft-
ware, version 9.2 (SAS Institute, Cary, North Carolina),
with P o 0.05 considered statistically signiﬁcant. The
protocol for this study was reviewed and approved by
the University of Utah Institutional Review Board.RESULTS
Of the 1.69 million patients with T2D in the Q-EMR
database during the study period, 28,314 had a new
prescription order for exenatide QW or liraglutide
between January 1, 2012, and March 31, 2013. There
were 5141 patients who met study inclusion criteria;
808 were newly prescribed exenatide QW, and 4333
were newly prescribed liraglutide (Figure 1). The larger
number of patients in the liraglutide group reﬂects, in
part, that liraglutide was approved for use in the United
States in 2010 versus 2012 for exenatide QW.
The 2 cohorts were similar in most baseline
characteristics, including age and sex (Table I).
Mean (SD) baseline HbA1c was 8.3% (1.5%) and
8.4% (1.6%) (P ¼ 0.66); mean (SD) baseline weight
was 107.6 (25.0) kg and 108.4 (24.8) kg (P ¼ 0.38)
for exenatide QW and liraglutide patients,
respectively. A higher proportion of liraglutide
patients had hypertension (73.6%) than exenatide
QW patients (70.0%) (P ¼ 0.04); however, baseline
systolic blood pressure and diastolic blood pressure
did not differ (Table I).3
Patients with T2D in the Q-EMR database between
January 1, 2012, and March 31,2013
N = 1.69 million
First prescription order for exenatide QW or liraglutide between
January 1, 2012, and March 31,2013 (Index date)
n = 28,314
≥ 13 months of clinical activity before index date
and ≥1 year of clinical activity after index date
n = 10,221
Age ≥18 years and no other exclusion criteria met
n = 18,856
GLP-1RA patients with available HbA1c values at index
date (-60/+30 days) and 1 year (±60 days) after index date
n = 5141
Exenatide QW cohort
n = 808
Liraglutide cohort
n = 4333
No prior GLP-1RA use and no indication of type1 diabetes or
gestational diabetes
n = 19,637
Figure 1. Patient cohort identification flowchart.
Exclusions (n excluded because of cri-
teria) were as follows: patients with
prescription orders for 2 GLP-1RAs on
the index date (n ¼ 151) and patients
with a prescription order for a non-
index GLP-1RA within 30 days after
index date (n ¼ 620). GLP-1RA ¼
glucagon-like peptide-1 receptor ago-
nist; HbA1c, glycosylated hemoglobin;
T2DM ¼ type 2 diabetes; QW ¼ once
weekly.
Clinical TherapeuticsInsulin was prescribed during the 13-month index
date period for 41.3% of the exenatide QW patients
and 43.2% of the liraglutide patients (P ¼ 0.34).
However, the proportion of patients initiating insulin
treatment on the index date was signiﬁcantly higher in
the liraglutide group (25.4% versus 2.0%; P o
0.001). A greater proportion of exenatide QW pa-
tients were prescribed metformin up to 13 months
before or on the index date (72.5%) compared with
the liraglutide group (67.1%; P ¼ 0.002).
There were slight differences in age between the
overall cohort and the insulin-naive subpopulations.
Mean (SD) age overall was 57.0 (10.9) years versus456.8 (10.8) years in the insulin-naive subpopulation
with baseline HbA1c Z7.0%. Age was numerically
lower in the insulin-naive subpopulation with baseline
HbA1c Z9.0% at 54.4 (10.8) years. There were more
men in the insulin-naïve population than in the overall
cohort (46.5% in the overall cohort and 50.1% and
52.1% in the insulin-naive cohorts with baseline
HbA1c Z7.0% and Z9.0%, respectively). Finally,
more patients were treated by primary care practi-
tioners in the insulin-naive cohort than in the overall
cohort (48.9% in the overall cohort and 65.8% and
70.2% in the insulin-naive cohorts with baseline
HbA1c Z7.0% and Z9.0%, respectively).
Glycemic Control
At 1-year follow-up, mean observed HbA1c reduc-
tion was 0.5% for both groups (SDs of 1.5 and 1.6 for
the exenatide QW and liraglutide cohorts, respectively;
P ¼ 0.75) (Figure 2). Furthermore, the proportion of
patients attaining HbA1co7.0% at 12 months did not
differ between groups and was 31.4% for the exenatide
QW patients versus 30.6% for the liraglutide patients
(P ¼ 0.65) (Figure 3).
In the subset of 376 exenatide QW and 1098
liraglutide insulin-naive patients with baseline HbA1c
Z7.0%, mean (SD) unadjusted HbA1c reduction at
1 year was also similar. A mean (SD) HbA1c reduction of
0.7% (1.5) from a baseline of 8.6% (1.3) was observed
for exenatide QW patients, and a 0.7% (1.6) reduction
from a baseline of 8.7% (1.4) was seen with liraglutide
(P ¼ 0.81) (Figure 2). However, the proportion of
patients attaining HbA1c o7.0% was signiﬁcantly
higher for exenatide QW patients (30.6%) than for
liraglutide patients (24.1%; P ¼ 0.01) (Figure 3).
In 107 exenatide QW and 369 liraglutide patients
with poorly controlled diabetes (baseline HbA1c
Z9.0%) who were insulin naive, mean (SD) unad-
justed baseline HbA1c values were 10.3% (1.1) and
10.2% (1.2) for the exenatide QW and liraglutide
cohorts, respectively, and HbA1c change was more
pronounced, with reductions of 1.4% (1.8) and 1.5%
(1.9), respectively (P ¼ 0.61 for reduction between
groups) (Figure 2). Of these, 14.0% of exenatide QW
and 12.7% of liraglutide patients attained HbA1c
o7.0% at 12 months (P ¼ 0.73) (Figure 3),
whereas 60.7% and 64.0% attained follow-up HbA1c
o9.0%, respectively (P ¼ 0.54) (data not shown).
On the basis of linear regression analysis of the
overall cohort controlling for age, sex, baseline HbA1cVolume ] Number ]
Table I. Baseline characteristics of patients newly prescribed exenatide QW or liraglutide.
Characteristic
Overall
(N ¼ 5141)
Exenatide QW
(n ¼ 808)
Liraglutide
(n ¼ 4333) P
Age, mean (SD), y 57.0 (10.9) 57.1 (10.6) 57.0 (11.0) 0.73
Age Z65 y 1353 (26.3) 203 (25.1) 1150 (26.5) 0.70
Male, no. (%) 2388 (46.5) 394 (48.8) 1994 (46.0) 0.15
Race, no. (%)
White 3614 (70.3) 572 (70.8) 3042 (70.2) 0.11
Black 375 (7.3) 44 (5.4) 331 (7.6)
Hispanic 208 (4.0) 28 (3.5) 180 (4.2)
Other 143 (2.8) 27 (3.3) 116 (2.7)
Unknown 801 (15.6) 137 (17.0) 664 (15.3)
Baseline HbA1c, mean (SD), % 8.4 (1.6) 8.3 (1.5) 8.4 (1.6) 0.66
HbA1c o7.0%, no. (%) 873 (17.0) 122 (15.1) 751 (17.3) 0.19
HbA1c Z7% to o9, no. (%) 2733 (53.2) 450 (55.7) 2283 (52.7)
HbA1c Z9.0%, no. (%) 1535 (29.9) 236 (29.2) 1299 (30.0)
BMI, mean (SD), kg/m2 37.7 (7.7) 37.2 (7.6) 37.8 (7.7) 0.04
Weight, mean (SD), kg 108.3 (24.8) 107.6 (25.0) 108.4 (24.8) 0.38
Systolic blood pressure, mean (SD), mm Hg 128.7 (15.4) 128.2 (15.3) 128.8 (15.4) 0.32
Diastolic blood pressure, mean (SD), mm Hg 76.3 (9.6) 76.0 (9.3) 76.4 (9.6) 0.30
Patients’ practitioner specialty
Primary care 2516 (48.9) 351 (43.4) 2165 (49.9) o0.001
Endocrinology 1932 (37.6) 368 (45.5) 1564 (36.1)
Other/unknown 693 (13.5) 89 (11.0) 604 (14.0)
Comorbidities, no. (%)
Hypertension 3753 (73.0) 566 (70.0) 3187 (73.6) 0.04
Acute MI 30 (0.6) 7 (0.9) 23 (0.5) 0.31
Cardiovascular disease 426 (8.3) 71 (8.8) 355 (8.2) 0.57
Cerebrovascular disease 83 (1.6) 16 (2.0) 67 (1.5) 0.36
Kidney disease 529 (10.3) 79 (9.8) 450 (10.4) 0.60
Hyperlipidemia 4273 (83.1) 668 (82.7) 3605 (83.2) 0.71
Stroke 44 (0.9) 11 (1.4) 33 (0.8) 0.10
Neuropathy or retinopathy 390 (7.6) 52 (6.4) 338 (7.8) 0.18
Charlson Comorbidity Index, mean (SD) 0.9 (1.3) 0.9 (1.3) 0.9 (1.3) 0.30
Charlson Comorbidity Index, no. (%)
0 2742 (53.3) 449 (55.6) 2293 (52.9) 0.28
1 1097 (21.3) 158 (19.6) 939 (21.7)
2 701 (13.6) 116 (14.4) 585 (13.5)
Z3 601 (11.7) 85 (10.5) 516 (11.9)
Baseline insulin use
Prescribed before index date 2204 (42.9) 334 (41.3) 1870 (43.2) 0.34
Started on index date 1115 (21.7) 16 (2.0) 1099 (25.4) o0.001
No baseline insulin 1822 (35.4) 458 (56.7) 1364 (31.5) o0.001
Other baseline diabetes medication use, no. (%)
Metformin 3493 (67.9) 586 (72.5) 2907 (67.1) 0.002
Sulfonylurea 2063 (40.1) 344 (42.6) 1719 (39.7) 0.12
(continued)
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Table I. (continued).
Characteristic
Overall
(N ¼ 5141)
Exenatide QW
(n ¼ 808)
Liraglutide
(n ¼ 4333) P
Thiazolidinediones 697 (13.6) 95 (11.8) 602 (13.9) 0.10
Dipeptidyl peptidase-4 inhibitors 1491 (29.0) 266 (32.9) 1225 (28.3) 0.008
Pramlintide 61 (1.2) 9 (1.1) 52 (1.2) 1.00
Other oral agents* 209 (4.1) 40 (5.0) 169 (3.9) 0.17
BMI, body mass index; HbA1c, glycosylated hemoglobin; MI, myocardial infarction; QW, once weekly.
*Other oral agents include α-glucosidase inhibitors, dopamine agonists, and meglitinide analogues. Sodium glucose co-
transporter 2 inhibitors were not available at the time of the study.
Clinical Therapeuticsand weight, practitioner specialty, coronary heart
disease, microvascular complications, CCI, and base-
line use of insulin and oral diabetes medications, the
estimated adjusted mean HbA1c reduction at 1 year
did not differ between exenatide QW and liraglutide
(Table II). At 1-year follow-up, the adjusted mean
HbA1c change was 0.37 (95% CI, 0.53 to 0.21)
for exenatide QW and 0.37% (95% CI, 0.55 to
0.18) for liraglutide (Table II). Insulin-naive patients
with baseline HbA1c Z9.0% had adjusted mean
HbA1c changes of 1.73% (95% CI, 2.39 to
1.06) for exenatide QW and 1.57% (95% CI,
2.29 to 0.86) for liraglutide (Table II).0.0%
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Figure 2. Percentages of patients attaining
HbA1co7.0% overall and for subsets
of Insulin-naive patients with baseline
HbA1c Z7.0% and Z9.0%. HbA1c,
glycosylated hemoglobin; QW ¼
once weekly.
6Multivariate logistic regression analysis of patients
with baseline HbA1c Z7.0% found no difference
between exenatide QW and liraglutide in the
likelihood of having a 1-year follow-up HbA1c
o7.0% (odds ratio, 1.04; 95% CI, 0.85–1.28) (data
not shown).Weight
Mean weight loss at 1 year of follow-up was
assessed in patients with documented weight values
at baseline and follow-up. No signiﬁcant difference
was observed between groups with a mean (SD)
weight loss of 2.3 (6.4) kg in the exenatide QW group
versus 2.3 (7.1) kg in the liraglutide group (P ¼ 0.98).______________________Insulin Naive_____________________ 
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Figure 3. HbA1c change from baseline to 12
months overall and for subsets of
insulin-naive patients with baseline
HbA1c Z7.0% and Z9.0%. HbA1c,
glycosylated hemoglobin; QW ¼ once
weekly.
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Table II. LS mean change in HbA1c and weight at 12 months for patients treated with exenatide QW or liraglutide.
Variable
Exenatide QW Liraglutide Treatment Difference
PLS Mean (SE) 95% CI LS Mean (SE) 95% CI LS Mean (SE) 95% CI
HbA1c, %
Overall (N ¼ 5141)
Unadjusted* 0.48 (0.02) 0.53 to 0.43 0.46 (0.05) 0.57, 0.35 0.02% (0.06) 0.13 to 0.10 0.76
Adjusted† 0.37 (0.08) 0.53 to 0.21 0.37 (0.09) 0.55, 0.18 0.09 (0.07) 0.26 to 0.08 0.98
Insulin-naive baseline Z7.0%
(n ¼ 1474)
Unadjusted* 0.67 (0.05) 0.76 to 0.58 0.69 (0.08) 0.85, 0.53 0.02% ( 0.09) 0.16 to 0.20 0.84
Adjusted† 0.71 (0.19) 1.09 to 0.33 0.80 (0.20) 1.20, 0.41 0.09% ( 0.08) 0.26 to 0.08 0.29
Insulin-naive baseline Z9.0%
(n ¼ 476)
Unadjusted* 1.54 (0.10) 1.73 to .35 1.43 (0.18) 1.79, 1.08 0.10% ( 0.20) 0.50 to 0.30 0.68
Adjusted† 1.73 (0.34) 2.39 to 1.06 1.57 (0.36) 2.29, 0.86 0.16% ( 0.20) 0.23 to 0.54 0.43
Weight, kg
Overall (N ¼ 5141)
Unadjusted* 2.25 (0.11) 2.47 to 2.04 2.26 (0.25) 2.75 to 1.77 0.005 (0.27) 0.53 to 0.54 0.98
Adjusted† 2.22 (0.43) 3.06 to 1.37 2.21 (0.49) 3.18 to 1.23 0.009 (0.28) 0.56 to 0.54 0.99
HbA1c, glycosylated hemoglobin; LS, least squares; QW, once weekly.
*Univariate linear regression.
†Multiple linear regression adjusted for age, sex, baseline HbA1c, baseline weight, practitioner type, coronary heart disease neuropathy or retinopathy, Charlson
Comorbidity Index, insulin prescription on and before index date, and number of noninsulin diabetes drug classes.
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Clinical TherapeuticsOn the basis of a multivariate linear regression
analysis controlling for age, sex, baseline HbA1c and
weight, practitioner specialty, coronary heart disease,
microvascular complications, CCI, and baseline use of
insulin and oral diabetes medications, adjusted mean
weight change at 1 year was 2.22 kg (95% CI,
3.06 to 1.37) for exenatide QW. Liraglutide
patients experienced a similar reduction of 2.21 kg
(95% CI, 3.18 to 1.23) (Table II).DISCUSSION
This retrospective analysis of 45000 patients with
T2D newly prescribed exenatide QW or liraglutide
found that both GLP-1RAs resulted in statistically
signiﬁcant and equal reduction in HbA1c at 1 year of
0.37%. They were both also associated with signiﬁcant
weight reduction of 2.2 kg. In the subset of insulin-
naive patients with poorly controlled diabetes (HbA1c
Z9.0%), HbA1c reduction was notably greater with
adjusted HbA1c mean reductions of 1.73% for exena-
tide QW and 1.57% for liraglutide. Although not an
unexpected ﬁnding, these data add to the literature
because glycemic outcomes associated with these
GLP-1RAs in patients with poorly controlled diabetes
are limited overall and for insulin-naive patients.
These real-world outcomes differed from those ob-
served in a head-to-head randomized clinical trial
(RCT).9 First, HbA1c reductions were not as
pronounced in this real-world study, possibly because
of less than optimal medication adherence and treat-
ment inertia. In addition, many patients in this study
had used multiple diabetes medications, including in-
sulin. These observations suggest that patients in this
real-world study had progressed to diabetes and were
possibly more difﬁcult to treat than patients in the RCT.
In a head-to-head RCT, a modest but signiﬁcantly
greater reduction in HbA1c for liraglutide compared
with exenatide QW was also identiﬁed (difference,
0.21%; 95% CI, 0.08%–0.33%).9 This difference was
not observed in the present study or in other
observational studies. A recent study by Saunders
et al11 also observed a signiﬁcant reduction in
HbA1c with exenatide QW or liraglutide at 6
months but with no difference in adjusted HbA1c
change (0.64% [1.32%] versus 0.65% [1.31%]).
A network meta-analysis of RCTs and observational
studies also failed to identify a difference in glycemic
control in effectiveness.13 This lack of agreement may8reﬂect differences in real-world medication adherence
as driven by dosing schedules. Although adherence
data are limited, an observational cohort study by
Johnston et al10 found that patients taking liraglutide,
which is dosed daily, were 20% less likely to be
adherent to therapy than exenatide QW patients (odds
ratio, 0.80; P o 0.001).
A notable study ﬁnding was that the proportion of
patients who initiated insulin treatment on the index
date was higher with liraglutide (25.4%) than with
exenatide QW (2.0%). Insulin treatment initiation on
the index date could have resulted in a greater
proportion of patients attaining HbA1c o7.0% and
greater mean HbA1c reduction in the liraglutide
group, assuming insulin was titrated to facilitate
HbA1c reduction. However, this was not observed.
This study assessed HbA1c change in all patients
using exenatide QW or liraglutide, including patients
with HbA1c o7.0%, who may have started therapy
primarily for weight reduction versus improvement in
glycemic control. A post hoc descriptive analysis
conducted in this group found a modest mean increase
in HbA1c at 12-month follow-up of 0.3% (SDs, 1.1%
with exenatide QW and 1.0% with liraglutide) from a
mean (SD) baseline HbA1c of 6.3% (0.5%) and 6.4%
(0.4%), respectively. Thus, including patients with
HbA1c o7.0% may have slightly attenuated HbA1c
outcome results.
There are several practice implications from the
ﬁndings of this study. In patients with T2D treated in
usual care settings, treatment with exenatide QW or
liraglutide leads to meaningful reductions in HbA1c and
weight, but the real-world effectiveness of these products
does not differ. Thus, it may be appropriate to base
treatment selection on other factors, such as dosing
preference, adherence concerns, tolerability, and patient
out-of-pocket costs. Furthermore, the pronounced re-
sponse to either GLP-1RA in insulin-naive patients with
HbA1c Z9.0% suggests that exenatide QW or liraglu-
tide may be a reasonable alternative to insulin. This
approach may be appropriate when avoidance of
hypoglycemia and/or weight gain is a therapeutic prior-
ity and is consistent with American Association of
Clinical Endocrinologists’ guidelines.3
A strength of this study is in the use of a large
population of patients with T2D from a national
EMR database. Although not nationally representa-
tive, the study has good generalizability for patients
with T2D predominantly treated in the primary careVolume ] Number ]
C. McAdam-Marx et al.setting. In addition, our prespeciﬁed subgroup analy-
ses enhance the application of ﬁndings to a usual care
setting where clinicians may treat a variety of patients,
including those who are insulin naive with inad-
equately controlled T2D.
This comparative effectiveness study provides val-
uable information to payers, clinicians, and patients to
compare outcomes between commonly used GLP-
1RAs in clinically and demographically diverse pa-
tients. This study also considers outcomes during a
1-year follow-up period versus 6-month outcomes,
which is also a consideration in the usual care setting.
This study’s observational study design using EMR
data is also associated with a number of limitations.
First, data on key factors that inﬂuence diabetes
outcomes are not systematically captured in EMR
databases, including adherence to diet and exercise
recommendations. Furthermore, the database used for
this study includes information on medications pre-
scribed but not on medications dispensed. Thus, it was
not possible to control for medication adherence.
In addition, this study was not designed to assess
outcomes of concomitant GLP-1RA and other diabe-
tes medications; thus, we did not assess the effects of
starting new classes of medications after the index
data, which could bias results. In a post hoc analysis,
we assessed outcomes in 457 patients who initiated
insulin treatment at any time during the follow-up
period because insulin was the class most commonly
initiated after index date and generally associated with
the greatest improvement in glycemic control. In this
subgroup, the mean (SD) HbA1c change was 0.25%
(1.7%); thus, we do not believe that postindex treat-
ment initiation had an appreciable effect on outcomes.
Channeling bias is also possible because of the
differences in approval dates of exenatide QW and
liraglutide. More patients may have been prescribed
liraglutide because of the longer time it has been
available, resulting in more prescriber experience. In
the present study, primary care practitioners pre-
scribed liraglutide more frequently than endocrinolo-
gists, whereas the opposite was true for exenatide
QW. It is likely that the endocrinology population had
more difﬁcult to control diabetes and/or received
different levels of treatment and support with endo-
crinologist versus primary care physicians, which
could also inﬂuence outcomes. However, baseline
HbA1c and CCI were not different between the treat-
ment groups despite the differences in practitioner] 2016specialty, and we used multivariate analysis to help
control for this and other confounding bias.
A risk of measurement bias may have been intro-
duced by allowing HbA1c values documented up to
30 days after the index date to be used as the baseline
HbA1c, which could underestimate the true treatment
effect. We therefore assessed HbA1c change in a post
hoc analysis using a shortened post–index date HbA1c
window of 7 days. In these analyses, results did not
differ, suggesting that using the extended post–index
date baseline HbA1c window did not affect outcomes.
Key reasons that exenatide QW and liraglutide
patients were not included in the ﬁnal cohort was
inadequate duration of follow-up and missing HbA1c
data to assess outcomes. This could introduce selec-
tion bias because included patients may differ from
the larger population from which it was drawn.
Although a full assessment of clinical differences is
not possible because patients with limited duration of
follow-up would likely have less complete records, we
were able to compare basic demographic data be-
tween the population of newly treated exenatide QW
and liraglutide patients with T2D (n ¼ 19,637). We
found that the study cohort is reasonably similar to
the sampled group of patients. The mean (SD) age of
the study cohort was slightly higher at 57.0 (10.9)
years versus 55.4 (11.4) years in the sampled pop-
ulation, and the mean (SD) CCI in the study cohort
was slightly lower at 0.9 (1.3) versus 1.2 (1.4) in the
sampled population. Sex and race mix were fairly
similar, with the study cohort being 46.9% male,
70.8% white, and 5.5% black versus 45.9% male,
68.8% white, and 9.0% black in the sampled pop-
ulation. Finally, since the initiation of this study,
2 additional GLP-1RAs were introduced to the US
market: albiglutide and dulaglutide. Patients treated
with these newer agents were not included because of
a lack of follow-up data, and results from this study
do not apply to the newer agents.
This real-world analysis of patients with T2D newly
treated with exenatide QW or liraglutide identiﬁed no
difference in glycemic control or weight outcomes at
1 year between these agents, although insulin was
prescribed more frequently with liraglutide. Further-
more, more pronounced glycemic response was seen in
insulin-naive patients with poorly controlled T2D.
Although factors such as tolerability and dosing fre-
quency differentiate these agents, either agent may be a
reasonable alternative for the treatment of T2D,9
Clinical Therapeuticsparticularly when improved glycemic response with
weight loss and low risk of hypoglycemia is desired.ACKNOWLEDGMENTS
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